Jim Cramer Discusses These 18 Stocks & President Trump’s $500 Billion AI Plan

Page 9 of 17

9. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q3 2024: 81

Johnson & Johnson (NYSE:JNJ) is a global healthcare giant. While the firm has faced a lot of turmoil in 2024, primarily because of a multi-billion dollar talcum powder lawsuit, it has nevertheless managed to grow. So far, 2025 has been an eventful year for Johnson & Johnson (NYSE:JNJ). The firm kicked off the year by announcing a massive $14.6 billion acquisition attempt of a neuropsychiatric drug manufacturer. Then, its shares fell by 4% despite Johnson & Johnson (NYSE:JNJ) beating Q4 analyst expectations for revenue and earnings. The shares fell as a 25-cent hit to projected 2025 earnings surprised investors. Here is what Cramer said:

“But they [Procter & Gamble] are better than we thought. You know versus JNJ which is still having a problem with China.

“Because right now it’s China, until today, I have felt that if you have done a lot of business in China I just have to count you as having a bad year-over-year. And I think JNJ’s being hurt by that. And I don’t think JNJ’s being hurt, I think it’s a little unfair, I think that stock’s down too much.

Page 9 of 17